Activity-Specified Formulation and Manufacturing
KS Nutripharma develops and manufactures digestive enzyme supplements for OEM, ODM, and private-label projects. We help brands define enzyme activity targets, align assay methods, assess dosage-form feasibility, and establish the specifications needed for a comparable manufacturing quote.
Start with an existing label, a supplier specification, or a new product concept. The first reply identifies the specification gaps and confirms whether the next step is a formulation review or a quotation. A complete activity specification is not required before that reply.
How to Compare Digestive Enzyme Supplement Quotes
Use this review when two quotations are in hand. It identifies specification gaps, distinguishes a price difference from a scope difference, and sets a comparable basis for quotation. The status below is a purchasing assessment of the information provided. It is not a laboratory conclusion and not a promise of shelf-life performance.
Check | What must align | If it does not |
|---|---|---|
| Material identity | Enzyme, source, and the raw-material specification where it changes the fill | The quotations may not cover the same material |
| Activity specification | Activity unit, assay method, and applicable test conditions | The results may not be directly comparable |
| Finished-product target | Activity per serving, serving size, and dosage form | Similar blend weights do not establish equivalent specifications |
| Testing responsibility | Who performs raw-material screening, in-process control, and finished-product activity testing | The quotations may cover different testing scopes. Confirm whether added testing is required before comparing price |
| Shelf-life requirement | Release target, any end-of-shelf-life target, and the evidence that target relies on | The stability work in each quotation may differ |
| Commercial scope | Quantity basis, packaging, testing fees, and the lead-time start point | A lower price may cover a narrower scope |
Quote comparability status:
- Comparable. The key activity specifications and commercial terms are aligned.
- Partially comparable. One or more specifications or service items remain unresolved.
- Not yet comparable. Material differences remain in the activity target, the assay basis, or the finished-product testing scope.
Send an existing label or supplier specification as an existing-formula inquiry. Send a concept without activity targets as a new-product inquiry.
Choose the Formula Direction
The direction decides which activity targets, tests, and label lines are on the quotation. These are starting points for SKU development, not fixed formulas, and not a statement of physiological effect.
Where the project starts | Route to assess | Confirm first |
|---|---|---|
| A daily broad-spectrum product, from a concept | Broad-spectrum | Core enzymes, the activity target for each, and the fill per serving |
| The formula must exclude animal pancreatin and a gelatin capsule | Plant-based | Enzyme source, carrier, processing aids, capsule shell, and the supplier documents |
| The product is for use with dairy-containing meals | Lactase-focused | Lactase activity, directions for use, and the dosage form |
| The product is for selected beans and vegetables | Alpha-galactosidase | The activity target, the supplier’s assay method, and the directions for use |
| A broad formula already exists and needs higher protease and lipase activity | Protein- and fat-focused | A separate activity target and method for each enzyme, and the added tests |
Best fit: A first broad-spectrum SKU built around protease, amylase, and lipase.
Key specifications: The activity target per serving, the fill weight, and the minimum activity required at the end of shelf life.
Development considerations: Start with protease, amylase, and lipase. Add cellulase, hemicellulase, glucoamylase, or invertase only when the brief justifies the additional activity targets, testing, and label complexity.
Starting format: Hard capsule.
Best fit: A formulation that excludes animal pancreatin and a gelatin capsule.
Key specifications: The source of every enzyme, microbial or plant, plus the carrier, the processing aids, and an HPMC or pullulan shell. Obtain supplier documentation for the vegan status the brand requires for each ingredient and processing aid.
Development considerations: A vegan claim depends on that documentation and is reviewed against the brand’s criteria. Additional enzymes such as cellulase, hemicellulase, or pectinase can be considered when they fit the intended formula and product positioning.
Starting format: HPMC or pullulan capsule.
Best fit: A product for use with dairy-containing meals that needs its own lactase activity target and directions for use.
Key specifications: The lactase activity target per use, and directions that match that use.
Development considerations: Flavor, acidity, and disintegration are dosage-form attributes. They are specified with the format, not as part of the lactase activity target.
Starting format: Chewable tablet.
Best fit: A product for selected beans and vegetables, built on alpha-galactosidase activity.
Key specifications: Directions for use that name those foods, and the assay named on the supplier specification.
Development considerations: The activity target, the directions for use, and the testing method need to describe the same use.
Starting format: Capsule or tablet.
Best fit: An existing broad-spectrum product line that needs a separate SKU with higher specified protease and lipase activities.
Key specifications: Protease and lipase activity, each with its applicable unit and assay method. Bromelain or papain is added only when the brief needs a plant protease, on the assay named for that enzyme.
Development considerations: Adding either plant protease introduces another activity specification and may increase testing costs. Pancreatin, ox bile, and betaine hydrochloride follow a different formula route, with the betaine, pancreatin, and ox bile formulas.
Starting format: Hard capsule.
A broad-spectrum blend puts several enzyme activities in one product. Each enzyme still needs its own activity target and assay method, so the specification and the testing can be more involved.
A dedicated enzyme product stays on one activity and its directions for use. The specification is narrower, and the product is still a separate SKU with its own quantity, packaging, and testing.
If both routes are under consideration, name them together with the target market, the dosage form, and the expected quantity, so the quotations use the same commercial basis.
Choose the Digestive Enzyme Format: Capsules, Chewables, Tablets or Powder
A format is quoted when the activity target can be specified for that process. Capsules, chewables, tablets, and powders are the usual paths. Stick packs require a separate packaging run and their own minimum quantity.
Hard CapsulesBest for: The broad capsule, the vegan capsule, and the higher protease and lipase blend.
Key specifications: Activity per serving, fill weight, capsule size, and the shell: gelatin, HPMC, or pullulan.
Feasibility and cost drivers: The capsule is filled with a dry blend. A standard hard capsule should not be treated as a validated acid-protection or delayed-release system. Delayed-release capsules require a separate capsule specification covering the release mechanism, process controls, moisture requirements, and incremental cost.
Quote inputs: Whether storage or distribution requires moisture protection. Quantity and production lead time are in the table below. The hard-capsule process is the reference.
ChewablesBest for: The lactase-focused formula.
Key specifications: Activity per tablet, flavor, acidity, disintegration, and tablet weight.
Feasibility and cost drivers: Flavor, acidity, and disintegration are separate from the lactase activity. A flavor the development sample does not accept changes the tablet specification.
Quote inputs: Flavor approval on the development sample. Chewables use the tablet quantity and the tablet production lead time below.
TabletsBest for: A swallowed lactase or alpha-galactosidase tablet.
Key specifications: Activity per tablet, disintegration, hardness, and friability.
Feasibility and cost drivers: A swallowed tablet avoids the flavoring requirements of a chewable. Friability and the enzyme load are confirmed on the same trial.
Quote inputs: Confirm that the tablet is swallowed rather than chewed. Tablets cover both swallowed tablets and chewables.
PowdersBest for: A powder assessed after a capsule specification, or a single-enzyme powder.
Key specifications: Activity per scoop or per stick, taste, flow, and the packaging barrier.
Feasibility and cost drivers: Taste, flow, moisture limits, and the barrier are assessed together. Moisture and packaging requirements should be defined before the final specification and production scope are confirmed.
Quote inputs: Bulk powder starts at 2,000 pieces or 2,000 bottles. The quotation names one of those bases. Stick packs start at 10,000 sticks, and stick-pack timing is set after the film and the fill are chosen. Process detail sits on powders and granules.
Gummies, softgels, liquids, and an enzyme–probiotic capsule are quoted outside the five directions above.
- Gummies. Activity retention is evaluated on material processed under representative gummy-manufacturing conditions, and again through storage. A capsule specification is not transferred into a gummy.
- Softgels. Reviewed only when the formula is compatible with an oil-phase fill and the available process, on softgels.
- Liquids. Preservative compatibility, enzyme activity, and storage conditions are reviewed together. Minimum quantity and lead time are confirmed for each liquid project.
- Enzyme–Probiotic Combinations. Strain identity, processing compatibility, moisture requirements, and stability are reviewed before a combined SKU is quoted. A spore-forming probiotic strain is one option to assess for a combined capsule, subject to compatibility and stability review. A high-CFU vegetative probiotic may require a separate SKU when shared processing or storage cannot meet both specifications. Strain identity and the count test are specified on the probiotic supplements page.
- Delivery Technologies. Acid protection, beadlets, and moisture barriers are reviewed under delivery systems when the formula requires them.
The testing plan is defined against the approved product specification, including the applicable enzyme activity units, analytical methods, and finished-product release criteria. Testing responsibilities are assigned according to the method’s suitability for the ingredient or finished-product matrix. Where external laboratory testing is required, the report is reviewed as part of the agreed quality documentation and release process. The finished-product COA and any supporting laboratory reports are provided according to the confirmed project scope.
Different activity units are not converted into one another. A raw-material COA does not replace a finished-product activity result. An end-of-shelf-life target, when required, needs a named test point and is not a guaranteed result.
When external laboratory testing is required, its timing is stated on the quote. That time sits outside the sample window and the production lead times below, unless the quotation includes it. Commercial production lead time begins only after the required analytical method and the specification have been agreed. When the external test is scheduled after production, it can extend batch release and delivery. The quote states whether that test falls before production, during production, or after it.
Meeting an agreed activity specification shows that the batch met that specification. It is not evidence of a clinical effect.
The label uses the activity unit specified for that enzyme and supported by the agreed assay method. A compendial method title is added only after it has been confirmed for the product.
Examples of Enzyme Activity Units
The units below are examples from supplier specifications. They are not a conversion table.
Enzyme | Unit on the specification |
|---|---|
| Protease | HUT or SAPU, as named for that material |
| Amylase | DU or SKB |
| Lipase | FIP or LU |
| Lactase | ALU, or the unit on the lactase specification |
| Cellulase | CU |
| Alpha-galactosidase | The unit on that supplier specification |
| Bromelain, papain | The unit named for that plant protease |
Results remain in the assay unit used for that enzyme. A result is not converted into another unit on the label.
The finished-product COA reports the test results and the specifications that apply to the released batch.
Information | What it is |
|---|---|
| Measured on the batch | A finished-batch result reported under the agreed method. Supporting laboratory reports are supplied according to the confirmed project scope |
| Supplier documents | The raw-material lot result: identity, activity, allergen, and contaminant statements received with that lot. A supplier statement is not an independent finished-product test unless the specification requires one |
| Calculated from the specification | Target activity per serving, fill weight, label targets, and any overage in the batch record. These are targets, not measured results |
Overage is established from process and stability data, not from a fixed default percentage. The decision considers the target market’s labeling requirements, the activity required at the end of shelf life, the actual process, packaging, storage conditions, and any relevant safety or specification limits.
A sample COA is not available for external distribution. Before quotation, the measured, supplier, and calculated lines, the test scope, the applicable release limits, and which results are batch-specific can be confirmed. Upload an existing label or COA when you want the specification basis assessed.
Each figure below is an indicative starting quantity on one count basis. A piece is one capsule, tablet, chewable, or gummy. The same figure can instead be a bottle count. The quotation names one basis. On a bottle count, it also states how many pieces are in each bottle. Five thousand pieces and five thousand bottles are separate orders. Stick packs are counted as sticks. Softgel and liquid quantities are set on the project.
The 6–8 week and 12–14 week windows are the current first-order production lead times for the formats in the table. They begin after the formula specification, packaging, artwork, and production slot have been confirmed and the order has been placed. Repeat-order production lead time applies when a repeat order uses the same formula and pack. Raw-material purchasing, external testing, stability work, and transit sit outside those windows unless the quotation includes them. Delayed-release capsules use the capsule row.
Format | Indicative starting quantity | Count basis | First-order production lead time | Repeat-order production lead time |
|---|---|---|---|---|
| Capsules, including delayed-release | 5,000 | Pieces or bottles | 6–8 weeks | 4–6 weeks |
| Tablets and chewables | 5,000–10,000 | Pieces or bottles | 6–8 weeks | 4–6 weeks |
| Powders | From 2,000 | Pieces or bottles | 6–8 weeks | 4–6 weeks |
| Stick packs | From 10,000 | Sticks | Set on the quote | Set on the quote |
| Gummies | 10,000 | Pieces or bottles | 12–14 weeks | 6–8 weeks |
| Softgels, oil phase only | Set on the project | Set on the project | 12–14 weeks | 6–8 weeks |
| Liquids | Set on the project | Set on the project | Set on the project | Set on the project |
None of the dates below is a delivery date. We do not offer a separate 500–1,000-unit commercial pilot or a standalone 1–2-week pilot run.
Stage | Timing | Output and condition |
|---|---|---|
| First reply | Within 24 hours on a business day | Fit, open points, a suggested format and pack, the quantity band, and the next step. Not a quotation. |
| Working quote | 3–5 days when the market, formula direction or label, dosage form, and quantity are already in the inquiry | Feasibility, quantity band, production window, and whether external laboratory testing is required. |
| NDA, if needed | 1–3 business days, before the sample specification is locked | Covers activity ratios, flavor systems, and delivery methods. |
| Development sample | About 7–10 business days after identity, unit, method, and dosage form are agreed | An approved sample or a revision list. Not for sale, and not a process-validation batch. |
| Stability pre-check, if needed | 2–4 weeks after the sample is in hand | A pack and formula recommendation, outside the sample window and the production lead times. |
| First manufacturing run | The first-order production lead time above | The starting quantity for that format, after sample approval and confirmation of the formula, process, and packaging. The quantity can move by project. |
Sample approval does not replace the activity checks on the first manufacturing run. After approval, the first manufacturing run still requires a confirmed formula, process parameters, and packaging direction. Special-material purchasing, external testing, and international shipping are included only when the quotation states them. A longer enzyme list, a gummy process check, a probiotic in the same pack, new packaging, or labels for more than one market can extend the window. The extension is named on the quote.
A result below the labeled activity is reviewed against the method, any overage in the batch record, and the heat and moisture of the actual process. Deviations are assessed against the agreed specification, the batch records, and the quality agreement. Corrective action, rework, or replacement follows the contract.
Packaging and product-specific process limits are confirmed before production. The selected pack must support the agreed storage and distribution conditions. Applicable humidity, water-activity, and process-temperature limits are documented in the product specification.
Available packaging options include HDPE bottles, glass, blisters, sachets, stick packs, pouches, and retail cartons. Where moisture protection is warranted, the usual choices are a bottle with a desiccant, an aluminum stick, or a blister. Non-GMO materials, a vegan shell, a gelatin-free gummy, a shorter ingredient line, and natural flavors are specified for the formula in question.
Documents are grouped by type, and only the items the specification or the shipment requires are included:
- Batch testing. The finished-product COA and the agreed microbial, heavy-metal, or enzyme-activity results, where applicable.
- Specification and supplier documentation. The activity specification, an allergen statement, and Non-GMO documentation, as applicable.
- Export and traceability. Papers supplied according to the destination market and the shipment.
Label support checks how the units are presented and flags disease-treatment wording. Copies of the certificates that apply to the manufacturing site are available with the quote. Those copies follow the site and the project. They are not issued automatically for every SKU. Facility registration is a site record. It is not a product approval.
After handover, storage and distribution remain with the brand unless the contract assigns them differently.
Request a Formulation Review or a Quotation
A complete activity specification is not required to start. The form is the same for both inquiries. Write “existing formula” or “new concept” in the requirement so the inquiry can be sorted. The brand owner remains responsible for the final label claims and their substantiation in each target market.
Existing Formula or Label
Send the label or specification, the target market, the dosage form, and the expected quantity. Upload a COA if you have one. The reply identifies specification gaps, the testing scope, and what is still missing from a comparable quotation.
Submit an existing formula or label.
New Product Concept
Send the target market, the product direction, the preferred dosage form, and the expected quantity. The reply recommends a formula route, a starting format, and the next feasibility step.
Related
Disclaimer
Wholesale and brand-manufacturing reference only. Dietary supplements are not drugs. Activity examples describe commercial specifications, not recommended intakes, and not evidence of a clinical effect. The brand owner is responsible for structure/function or other claim substantiation and for finished-label compliance in each destination market. Activity units follow the enzyme, the method, and the test point named in the specification. Facility registration is not a product approval.
Written by KS Nutripharma Formulation Team | Reviewed by KS Nutripharma Director of R&D (PhD, Food Science | 19+ years nutraceutical development) | Technical review scope: activity targets, assay methods, and the five formula directions. External laboratory testing, when required, is confirmed on the quotation | Updated October 2026 | R&D Center
